Bionano Genomics, Inc. (NASDAQ:BNGO) announced the publication of a special issue of Cancers journal focused on the impact of its optical genome mapping (OGM) on hematological malignancy research. The issue includes eight peer-reviewed publications, with three more expected, highlighting OGM's advantages over traditional cytogenetic methods. OGM is noted for its higher resolution, cost-efficiency, and potential to replace traditional methods. The research demonstrates OGM's concordance with traditional methods and its ability to identify additional pathogenic structural variants (SVs). Bionano's CMO and CEO commented on the significance of the findings for cancer research and cytogenetics.